All the news Showing 7 of 7 articles from: Pegylated interferon and ribavirinGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Elbasvir/grazoprevir superior to sofosbuvir and pegylated interferon/ribavirin Michael Carter / 10 May 2016 New research has demonstrated the clear superiority of an oral combination of direct-acting antivirals (DAAs) over a regimen that combines a DAA with pegylated interferon and ribavirin for the treatment of chronic hepatitis ... Treating HCV genotypes 2 and 3 in HIV/HCV co-infected people Liz Highleyman / 10 October 2013 People co-infected with HIV and HCV, mostly with hepatitis C virus (HCV) genotype 3, responded about as well as HIV-negative people to interferon-based therapy after taking into account other factors associated ... Hepatitis C treatment gap in Europe: France doing well but Italy treated fewer than one in a hundred patients in 2010 Caspar Thomson / 23 May 2013 France led the world in the proportion of its hepatitis C patients who received treatment in 2010, but some countries in southern and eastern Europe had treatment rates that were almost tenfold ... Low viral load in hepatitis C treatment: Is a third drug necessary? Rob Camp / 23 November 2012 When resources for hepatitis C treatment with new directly acting antivirals are limited, findings from the United States suggest that previously untreated people with low viral loads may stand a good chance ... No evidence of an interaction between abacavir and ribavirin Michael Carter / 17 July 2012 There is no evidence of an interaction between the anti-HIV drug abacavir and the anti-hepatitis C agent ribavirin, investigators report in the online edition of AIDS. Some earlier research reported poorer hepatitis C treatment ... Depression and pegylated interferon: doctors look at screening strategies and treatment Michael Carter / 09 May 2012 Patients with hepatitis C should be carefully evaluated for symptoms of depression before and during pegylated interferon-based therapy, investigators write in the International Journal of Interferon, Cytokine and Mediator Research. The authors also highlighted ... Interferon-lambda as effective as alpha but with much better safety profile in hepatitis C Michael Carter / 20 April 2012 A new form of pegylated interferon is associated with significantly fewer side-effects than the standard form of the drug, a study conducted in patients with the easier-to-treat hepatitis C genotypes shows. Data from ... ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive